Novo Nordisk turns up the heat on inlicensed Genmab drug with phase III preparations
![Photo: Novo Nordisk / PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article12832737.ece/ALTERNATES/schema-16_9/doc7ex74u8www914oijucx4.jpg)
At Novo Nordisk, preparations are being made to begin a phase III trial of candidate Mim8, which the Danish company hopes to make a blockbuster drug – a drug expected to reach sales of over USD 1bn a year.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.